Evidence map›Paper›PMID 39312022›Full record

ReviewHead and neck pathology2024

DEK::AFF2 Fusion-Associated Squamous Cell Carcinoma: A Case Series with Literature Review on an Emerging and Challenging Entity.

Sara E Amin, James S Lewis, Julia A Bridge, Jen-Fan Hang, Udit Naik, Justin A Bishop, Karan Saluja

Abstract readReview
In one paragraph

Review in Head and neck pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Resistance mechanism to pembrolizumab inInternational cancer conference journal · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Case Report: "Frontiers in immunology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sara E AminDepartment of Pathology and Laboratory Medicine, University of Texas Health Science Center at Houston, 6431 Fannin Street, Houston, TX, 77030, USA.
James S LewisDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Julia A BridgeDivision of Molecular Pathology, ProPath, Dallas, TX, USA.
Jen-Fan HangDepartment of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Udit NaikDepartment of Pathology and Laboratory Medicine, University of Texas Health Science Center at Houston, 6431 Fannin Street, Houston, TX, 77030, USA.
Justin A BishopDepartment of Pathology and Laboratory Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Karan SalujaDepartment of Pathology and Laboratory Medicine, University of Texas Health Science Center at Houston, 6431 Fannin Street, Houston, TX, 77030, USA. karan.saluja@uth.tmc.edu.ORCID http://orcid.org/0000-0002-2844-5234

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDEK::AFF2 fusion-associated squamous cell carcinoma (DEK::AFF2 SCC), also reported in the literature as low-grade papillary sinonasal (Schneiderian) carcinoma (LGPSC), is a rare, primarily bland-appearing, but locally aggressive neoplasm. Morphologically, these tumors can closely resemble sinonasal papilloma (SP), especially on small or limited biopsy, often leading to misdiagnosis. DEK::AFF2 SCC is devoid of the underlying mutually exclusive EGFR or KRAS driver mutations of SP, suggesting it may represent a distinct unique entity.

methodsIn this study, we conducted a retrospective search of "unusual" SP reported either as atypical, dysplastic, or suspicious for malignant transformation at our institution in the last 13 years (2010-2023), to identify potential cases of DEK::AFF2 SCC.

resultsOf the 201 SP cases during this time period, 30 "unusual" SP cases were identified. On morphologic review of these 30 cases, 6 were worrisome for DEK::AFF2 SCC and were selected for AFF2 immunohistochemical stain (IHC), of which 3 cases were positive. All 3 AFF2 IHC positive cases were also positive for DEK::AFF2 fusion by fluorescence in situ hybridization (FISH), thereby, confirming IHC results.

conclusionsThis study highlights that AFF2 IHC can be an invaluable surrogate marker to FISH in identifying DEK::AFF2 SCC in challenging cases to avoid misdiagnosis. Detailed clinical and pathologic data were collected to gain a better understanding of this emerging challenging entity. A literature review was performed to enrich our knowledge of DEK::AFF2 SCC.

Indexed as

Chromosomal Proteins, Non-HistoneOncogene ProteinsPoly-ADP-Ribose Binding ProteinsAdultAgedBiomarkers, TumorCarcinoma, Squamous CellFemaleHumansMaleMiddle AgedOncogene Proteins, FusionParanasal Sinus NeoplasmsRetrospective StudiesSquamous Cell Carcinoma of Head and NeckBiomarkers, TumorChromosomal Proteins, Non-HistoneDEK protein, humanOncogene ProteinsOncogene Proteins, FusionPoly-ADP-Ribose Binding ProteinsAFF2DEKDEK:AFF2 fusionFluorescence in situ hybridizationImmunohistochemistrySinonasal carcinomaSinonasal papilloma

Identifiers

PMID39312022
PMCPMC11420419

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.